诺和诺德为其下一代减肥药辩护:“它将是一款重要产品”

新浪财经
28 Mar

要点:诺和诺德(Novo Nordisk)为其备受炒作的下一代减肥药候选药物 CagriSema 令人失望的试验结果进行了辩护,坚称它将成为一种 “重要的” 减肥疗法。“我对 CagriSema 非常有信心,” 该公司首席执行官拉斯・弗鲁尔高・乔根森(Lars Fruergaard Jørgensen)在丹麦哥本哈根举行的公司年度股东大会上对股东们说道。“它对我们来说将是一款重要的产品。”...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10